$IMUX
Immunic Inc

2016 Q4 Form 10-Q Financial Statement

#000128077616000026 Filed on November 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.960M $2.770M $2.690M
YoY Change -3.27% 2.97% 4.67%
% of Gross Profit
Research & Development $8.860M $7.469M $9.646M
YoY Change 29.72% -22.57% -5.84%
% of Gross Profit
Depreciation & Amortization $410.0K $420.0K $325.0K
YoY Change 7.89% 29.23% 4.84%
% of Gross Profit
Operating Expenses $11.83M $10.24M $12.34M
YoY Change 19.57% -16.99% -3.71%
Operating Profit -$10.24M -$12.34M
YoY Change -16.99% -3.71%
Interest Expense $70.00K $80.00K $10.00K
YoY Change 250.0% 700.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $20.00K $61.00K $35.00K
YoY Change 100.0% 74.29% 191.67%
Pretax Income -$11.73M -$10.18M -$12.30M
YoY Change 18.97% -17.24% -3.91%
Income Tax
% Of Pretax Income
Net Earnings -$11.73M -$10.18M -$12.30M
YoY Change 18.98% -17.25% -3.89%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$14.66M -$12.89M -$20.50M
COMMON SHARES
Basic Shares Outstanding 32.05M shares 31.54M shares 24.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.00M $68.10M $59.80M
YoY Change -28.06% 13.88% -24.4%
Cash & Equivalents $59.99M $68.09M $59.75M
Short-Term Investments
Other Short-Term Assets $1.500M $1.400M $2.900M
YoY Change -6.25% -51.72% -17.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $61.46M $69.46M $62.61M
YoY Change -27.77% 10.95% -24.19%
LONG-TERM ASSETS
Property, Plant & Equipment $2.505M $2.922M $4.163M
YoY Change -34.23% -29.81% 39.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $58.00K $87.00K $171.0K
YoY Change -68.48% -49.12% -34.98%
Total Long-Term Assets $2.563M $3.009M $4.334M
YoY Change -35.81% -30.57% 33.44%
TOTAL ASSETS
Total Short-Term Assets $61.46M $69.46M $62.61M
Total Long-Term Assets $2.563M $3.009M $4.334M
Total Assets $64.03M $72.47M $66.94M
YoY Change -28.13% 8.26% -22.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $780.0K $1.193M $549.0K
YoY Change -36.12% 117.3% -21.12%
Accrued Expenses $4.656M $3.357M $7.380M
YoY Change -11.67% -54.51% -1.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.480M $4.630M $8.119M
YoY Change -17.66% -42.97% -4.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $99.00K $100.0K $146.0K
YoY Change -1.98% -31.51% -48.41%
Total Long-Term Liabilities $100.0K $83.00K $146.0K
YoY Change -0.99% -43.15% -48.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.480M $4.630M $8.119M
Total Long-Term Liabilities $100.0K $83.00K $146.0K
Total Liabilities $5.580M $4.713M $8.265M
YoY Change -17.41% -42.98% -5.88%
SHAREHOLDERS EQUITY
Retained Earnings -$243.8M -$232.1M -$193.0M
YoY Change 20.2% 20.26% 41.0%
Common Stock $3.000K $3.000K $2.000K
YoY Change 0.0% 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.45M $67.76M $58.68M
YoY Change
Total Liabilities & Shareholders Equity $64.03M $72.47M $66.94M
YoY Change -28.13% 8.26% -22.01%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$11.73M -$10.18M -$12.30M
YoY Change 18.98% -17.25% -3.89%
Depreciation, Depletion And Amortization $410.0K $420.0K $325.0K
YoY Change 7.89% 29.23% 4.84%
Cash From Operating Activities -$9.100M -$7.890M -$12.04M
YoY Change -2.05% -34.47% 7.6%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$270.0K -$310.0K
YoY Change 140.0% -12.9% -3.13%
Acquisitions
YoY Change
Other Investing Activities $20.00K $220.0K $340.0K
YoY Change -96.3% -35.29% -254.55%
Cash From Investing Activities -$100.0K -$50.00K $40.00K
YoY Change -120.41% -225.0% -107.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.100M 2.430M -190.0K
YoY Change -96.61% -1378.95% 1800.0%
NET CHANGE
Cash From Operating Activities -9.100M -7.890M -12.04M
Cash From Investing Activities -100.0K -50.00K 40.00K
Cash From Financing Activities 1.100M 2.430M -190.0K
Net Change In Cash -8.100M -5.510M -12.19M
YoY Change -134.22% -54.8% 3.83%
FREE CASH FLOW
Cash From Operating Activities -$9.100M -$7.890M -$12.04M
Capital Expenditures -$120.0K -$270.0K -$310.0K
Free Cash Flow -$8.980M -$7.620M -$11.73M
YoY Change -2.81% -35.04% 7.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32050850 shares
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9408000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
285098000 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1221000 USD
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1193000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5271000 USD
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3357000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8060000 USD
CY2016Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299768000 USD
CY2015Q4 us-gaap Assets
Assets
89081000 USD
CY2016Q3 us-gaap Assets
Assets
72473000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
85088000 USD
CY2016Q3 us-gaap Assets Current
AssetsCurrent
69464000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
92000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59754000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68088000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-42484000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15328000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250539 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5261910 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
321000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
15000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000 USD
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30473083 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31948855 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30473083 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31948855 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12307000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42172000 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10178000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29235000 USD
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
140000 USD
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
80000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
101000 USD
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
83000 USD
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
325000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
947000 USD
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
420000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1404000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000 USD
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-2000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2165000 USD
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1566000 USD
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2689000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9286000 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2770000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8257000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-397000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1562000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1890000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-84000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-78000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
344000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
144000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-523000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-515000 USD
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
79000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
214000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89081000 USD
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
101000 USD
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
83000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
206000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
12335000 USD
us-gaap Operating Expenses
OperatingExpenses
42231000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
10239000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-47000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11266000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1769000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
80000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-40661000 USD
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72473000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6655000 USD
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4630000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2292000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26672000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-12300000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42164000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-10178000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29235000 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000 USD
us-gaap Operating Expenses
OperatingExpenses
29441000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12335000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-42231000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10239000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29441000 USD
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1698000 USD
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
58000 USD
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
632000 USD
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
771000 USD
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
237000 USD
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
223000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
692000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
208000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
655000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
431000 USD
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000 USD
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000 USD
CY2015Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000 USD
CY2016Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
163000 USD
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
80000 USD
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.92
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
437000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.12
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000 USD
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1358000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
274000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11869000 USD
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12330000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3809000 USD
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2922000 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9646000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32945000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7469000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21184000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
533000 USD
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
18000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202856000 USD
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-232091000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2943000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3391000 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
163627 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2896618 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
47677 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1186999 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.73
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3294290 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3716520 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4847744 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.81
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3244500 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4736526 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2262963 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M11D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8098 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
82325000 USD
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
67760000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24025481 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23998396 shares
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31645838 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31153801 shares
CY2015Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2675000 USD
CY2016Q3 vtl Accrued Clinical Costs
AccruedClinicalCosts
1581000 USD
vtl Cash Equivalents Investments Maturity Period
CashEquivalentsInvestmentsMaturityPeriod
P3M
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
70000 USD
vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
23000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
110000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
25000 USD
vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0 USD
CY2015Q2 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
200000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
vtl Proceeds From Issuance Of Common Stock Net Of Stock Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
0 USD
vtl Proceeds From Issuance Of Common Stock Net Of Stock Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
11249000 USD
CY2015Q4 vtl Securities Offering Remaining Authorized Amount
SecuritiesOfferingRemainingAuthorizedAmount
165500000 USD
CY2016Q3 vtl Securities Offering Remaining Authorized Amount
SecuritiesOfferingRemainingAuthorizedAmount
154500000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-16-000026-index-headers.html Edgar Link pending
0001280776-16-000026-index.html Edgar Link pending
0001280776-16-000026.txt Edgar Link pending
0001280776-16-000026-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-093016xexhibit311.htm Edgar Link pending
vtl-093016xexhibit312.htm Edgar Link pending
vtl-093016xexhibit321.htm Edgar Link pending
vtl-093016xexhibit322.htm Edgar Link pending
vtl-20160930.xml Edgar Link completed
vtl-20160930.xsd Edgar Link pending
vtl-20160930_cal.xml Edgar Link unprocessable
vtl-20160930_def.xml Edgar Link unprocessable
vtl-20160930_lab.xml Edgar Link unprocessable
vtl-20160930_pre.xml Edgar Link unprocessable
vtl-93016x10q.htm Edgar Link pending